The interplay between cortisol, inflammation, and disease underscores the need for effective stress management to enhance ...

Findings reveal macrophages' role in immune modulation through bacterial metabolites, paving the way for improved therapies ...

A recent study has shed new light on the role of fibro-adipogenic progenitors (FAPs) in muscle regeneration, fibrosis, and degeneration.

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable ...

After four hours, the animals were euthanized, and peritoneal fluid was collected for total leukocyte count and TNF-α cytokine assay (Rodrigues et al., 2015). Animals in the UMB groups presented a ...

Q2 2025 Earnings Conference Call February 26, 2025 5:00 PM ETCompany ParticipantsSilviu Itescu - Chief Executive ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase ...

TNF Pharma begins phase 2b clinical trial to evaluate oral TNF-alpha inhibitor drug candidate isomyosamine: Baltimore Thursday, February 27, 2025, 18:00 Hrs [IST] TNF Pharmaceutic ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa contin ...

6 Isomyosamine is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an ...

today announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine as a treatment for chronic inflammation associated ...